Please be advised that Cytox Limited was placed into Liquidation on 4 January 2024, with Simon Farr and Anthony Collier of FRP Advisory Trading Limited being appointed Joint Liquidators of the Company. If you are owed money by Cytox Limited, or require further information about the Liquidation, please do not hesitate to contact firstname.lastname@example.org.
Jul 14, 2015
Cytox – The application of SNP profiling to risk stratification in Alzheimer’s disease to be presented at AAIC 2015
Development of SNP panel for clinical utility in Alzheimer’s disease risk assessment highlighted at Washington DC meeting
Oxford, UK. Cytox Ltd, an innovative developer of assays for risk assessment and prediction of dementia, has announced the timing of its poster presentation at the Alzheimer’s Association International Conference, AAIC 2015, Washington DC, USA, discussing the development of a customised SNP (single nucleotide polymorphism) array as an assay for risk of Alzheimer's disease (AD) and other dementias.
The poster, P3-108, “The Application of SNP Profiling to the Risk Stratification for Future Cognitive Decline in Mild Cognitive Impairment”, will be displayed on Tuesday 21st July, between 09.30am and 16:15pm (EDT), as part of the AAIC Diagnosis & Prognosis: Biomarkers (non-neuroimaging) Poster Session, in Exhibit Hall D, Walter E. Washington Convention Center, Washington, USA. The authors are Dr Valentina Escott-Price, Cardiff University, Cardiff, United Kingdom; Dr Richard Pither and Hiro Mori, Cytox Ltd, Oxford, United Kingdom; Professor Harald Hampel, Université Pierre et Marie Curie, Paris, France; Julie Davis, Cytox Ltd; Professor Rik Vandenberghe, Katholieke Universiteit Leuven, Belgium; and Professor John Hardy, UCL Institute of Neurology, London, United Kingdom. Dr Escott-Price will be available during the three poster sessions that day: 09.30 - 10.30am, 11.30am -14.00pm and 15.30 - 16.00pm for discussion.
The AAIC poster presents initial data from a wider research study to investigate the application of SNP profiling to risk stratification in AD.
Cytox leads a consortium, comprising Dr Zsuzsanna Nagy (University of Birmingham), Professor John Hardy and Dr Valentina Escott-Price, as an expert consultant in statistical genetics to the project team, which has received a substantial funding award from Innovate UK. The project aims to evaluate and validate the clinical utility of a customised genetic variation (SNP) panel associated with the mTOR signalling and other pathways in Mild Cognitive Impairment (MCI) in highly selected and characterised clinical samples. Dysregulation of the complex mTOR pathway has been identified as a risk factor for AD; differentially expressed mTOR pathway genes may regulate key functions linked to AD risk. MCI may be a prodromal state for AD and over half of these patients are at high risk of progression to AD. Current prognostic methods for AD are only 25-30% accurate in early MCI. The lack of validated biomarkers hampers clinical management of AD and the production of new therapies.
More information about the event can be found on the AAIC Conference website www.alz.org/aaic. More information about the presentation can be found after the Conference in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, www.alz.org/aaic/abstracts/abstr-archives.asp.